Bone formation is impaired in both type 1 and type 2 diabetes (T2D) while sclerostin, an antagonist of bone formation, is increased in T2D only. No data are available on latent autoimmune diabetes in adults (LADA), an autoimmune type of diabetes that may clinically resemble T2D at diagnosis. We evaluated serum sclerostin and bone turnover markers in LADA compared with T2D, and whether sclerostin is affected by metabolic syndrome (MetS) in T2D or LADA.
Serum sclerostin and bone turnover in latent autoimmune diabetes in adults
Defeudis, Giuseppe;
2018-01-01
Abstract
Bone formation is impaired in both type 1 and type 2 diabetes (T2D) while sclerostin, an antagonist of bone formation, is increased in T2D only. No data are available on latent autoimmune diabetes in adults (LADA), an autoimmune type of diabetes that may clinically resemble T2D at diagnosis. We evaluated serum sclerostin and bone turnover markers in LADA compared with T2D, and whether sclerostin is affected by metabolic syndrome (MetS) in T2D or LADA.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.